Abeona Therapeutics (ABEO) investor relations material

Executive summary

• ZEVASKYN, the first autologous cell-based gene therapy for RDEB, was approved in April 2025, with commercial launch delayed to Q4 2025 due to sterility test optimization.

• First commercial patient treated in December 2025, marking the start of commercial operations and launch momentum into Q1 2026.

• Growing patient demand, with over 100 eligible patients identified and four qualified treatment centers (QTCs) activated, including a new center in Texas expanding Gulf Coast access.

• No patient attrition or insurance denials reported; payer coverage is robust, including all major commercial and Medicaid plans.

Financial highlights

• Total revenue for 2025 was $5.8 million, including $3.4 million in license and other revenues and $2.4 million in net product revenue.

• Net income for 2025 was $71.2 million, or $0.34 per basic and $1.01 per diluted share, compared to a net loss of $63.7 million in 2024.

• $152.4 million gain recorded from the sale of a rare pediatric disease priority review voucher in June 2025.

• R&D spending decreased to $26.8 million in 2025 from $34.4 million in 2024, while SG&A expenses rose to $65 million, reflecting commercial transition.

• Cash, equivalents, and short-term investments totaled $191.4 million at year-end 2025.

Outlook and guidance

• Targeting at least seven QTCs active by end of 2026, with five additional centers in onboarding.

• Steady-state expectation is one to two patients treated per QTC per month, with some sites potentially reaching three.

• Profitability achievable at three or more patients treated per month, with $100 million annual burn rate as a reference.

• Anticipate improved efficiency and shorter timelines for patient treatment as QTCs gain experience and commercial foundations established in 2025 support scale-up.